| abstract |
A composition having a lipophilic agent with improved solubility and stability can be provided. For example, a non-aqueous composition comprising a lipophilic agent and an amphiphilic polymerizable solvent such as PEG400, but substantially free of organic solvents and insoluble particles may be provided. The composition can be further diluted with a desired aqueous diluent, such as an infusion solution for parenteral administration to a body such as a human. The composition may be suitable for the treatment of diseases or conditions sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases. |